Aerosolized antibiotics in mechanically ventilated patients
Authors:
- Gerald C. SmaldoneGSGerald C. Smaldone
- Sanford R. SimonSSSanford R. Simon
- Thomas G. O'RIordanTOThomas G. O'RIordan
- Ann CucciaACAnn Cuccia
- 1 January 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 26 (1) , 31-39
Abstract
To determine whether aerosolized antibiotics can be delivered efficiently to the lower respiratory tract in mechanically ventilated patients and to define possible clinical responses to these agents. Prospective serial study with cases as their own control. A 10-bed respiratory care unit for patients with chronic respiratory failure in a tertiary university hospital. Ventilator dependent patients who are otherwise medically stable. All subjects had a tracheostomy in place, were colonized with Gram-negative organisms, and produced purulent secretions which could be sampled daily. Six patients received nine courses of nebulized therapy, which consisted of treatments every 8 hrs of gentamicin (80 mg) or amikacin (400 mg) for 14 to 21 days. Doses to the lung were measured using radiolabeled aerosols and antibiotic concentrations in sputum. The response was assessed by a) changes in the volume of respiratory secretions; b) effect on bacterial cultures; and c) changes in the inflammatory cells and mediators of inflammation of the respiratory secretions (interleukin-1 beta [IL-1 beta], tumor necrosis factor-alpha [TNF-alpha], soluble intercellular adhesion molecule-1 [sICAM-1], and human leukocyte elastase). On average, patients inhaled 35.4 +/- 5.08% (SD) of the initial drug placed in the nebulizer (neb-charge). Of this neb-charge, 9.50 +/- 2.78% was found on the respirator tubing and tracheostomy tube and 21.9 +/- 7.15% was actually deposited in the lungs. The remainder of the neb-charge was sequestered in the nebulizer or exhaled. Trough sputum concentrations averaged 4.3 +/- 3.2 micro g/mL/mg neb-charge (range 234 to 520 micro g/mL) and increased to 16.6 +/- 8.1 micro g/mL/mg neb-charge (range 1005 to 5839 micro g/mL) immediately after therapy (p = .011). Serum concentrations were undetectable in most determinations except for a single patient who was in renal failure (8.7 micro g/mL amikacin). Treatment caused a significant reduction in the volume of secretions (p = .002). Weekly cultures revealed eradication of Pseudomonas species, Serratia marcescens, and Enterobacter aerogenes in most of the trials. Before antibiotic treatment, concentrations of IL-1 beta were higher than those reported in acute respiratory distress syndrome. Throughout the duration of the study, IL-1 beta correlated significantly with the absolute number of macrophages, neutrophils, and lymphocytes, respectively (r2 = .55, p = .002; r2 = .50, p < .0004, r2 = .36, p = .005). TNF-alpha concentrations correlated with lymphocytes and neutrophils, respectively (r2 = .27, p = .013, r2 = .21, p = .033). sICAM-1 concentrations increased twofold (p < .001) during treatment and then returned to baseline. The volume of secretions was related to neutrophil and IL-1 beta concentrations, respectively (r2 = .25, p = .008, r2 = .35, p = .006). Nebulizer delivery of aerosolized aminoglycosides is efficient and predictable. In our clinical model, aerosolized antibiotics can make a significant impact on respiratory secretions. Their efficacy in treatment of critically ill patients remains to be determined. (Crit Care Med 1998; 26:31-39)Keywords
This publication has 36 references indexed in Scilit:
- Increased levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) in tracheal aspirates of newborns with pneumoniaInfection, 1994
- Plasma interleukin‐1α and β, tumor necrosis factor‐α, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosisPediatric Pulmonology, 1994
- Cytokines in sputum and serum from patients with cystic fibrosis and chronic pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs.Pediatric Pulmonology, 1993
- Double-blind study of selective decontamination of the digestive tract in intensive careThe Lancet, 1992
- Selective decontamination of the digestive tract in the intensive care unitCritical Care Medicine, 1992
- A Controlled Trial in Intensive Care Units of Selective Decontamination of the Digestive Tract with Nonabsorbable AntibioticsNew England Journal of Medicine, 1992
- The Proinflammatory Cytokines Interleukin-l and Tumor Necrosis Factor and Treatment of the Septic Shock SyndromeThe Journal of Infectious Diseases, 1991
- The Effect of Oropharyngeal Decontamination Using Topical Nonabsorbable Antibiotics on the Incidence of Nosocomial Respiratory Tract Infections in Multiple Trauma Patients1987
- Aerosol delivery in intubated, mechanically ventilated patientsCritical Care Medicine, 1985
- Endotracheally Administered Antibiotics for Gram-Negative BronchopneumoniaChest, 1979